Clinically, metastatic NPC patients show elevated levels of NOTCH1+ CSC-CTCs (EPCAM+ EBNA1+ NOTCH1+ CD45<sup>-</sup>) and plasma FTO, suggesting their potential as blood-based biomarkers for monitoring disease progression and treatment response. This evidence concerns the gene NOTCH1 and nasopharyngeal carcinoma.